{"id":11871,"date":"2021-03-09T17:08:28","date_gmt":"2021-03-09T11:38:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11871"},"modified":"2021-07-24T12:58:18","modified_gmt":"2021-07-24T07:28:18","slug":"pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","title":{"rendered":"Overwhelming success of Gilead\/Kite&#8217;s Yescarta; Ridgeback\/ Merck in the COVID-19 game; AnaptysBio&#8217;s antibody-drug failure; Roche discards Tecentriq for bladder cancer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2c44ac7fd12\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2c44ac7fd12\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\/#Gileads_Kite_Receives_Expanded_Approval_for_its_CAR-T_Yescartas_in_Follicular_Lymphoma\" >Gilead&#8217;s Kite Receives Expanded Approval for its CAR-T Yescarta&#8217;s in Follicular Lymphoma&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\/#Promising_data_from_COVID-19_trial_reports_Ridgeback_and_Merck\" >Promising data from COVID-19 trial, reports Ridgeback and Merck&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\/#AnaptysBios_shares_plummeted_after_its_lead_drug_fails_in_rare_skin_inflammation_phase_II_trial\" >AnaptysBio\u2019s shares plummeted after its lead drug fails in rare skin inflammation phase II trial&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\/#After_AZ_Roche_discards_Tecentriq_for_Bladder_cancer_treatment\" >After AZ, Roche discards Tecentriq for Bladder cancer treatment&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gileads_Kite_Receives_Expanded_Approval_for_its_CAR-T_Yescartas_in_Follicular_Lymphoma\"><\/span><strong>Gilead&#8217;s Kite Receives Expanded Approval for its CAR-T Yescarta&#8217;s in Follicular Lymphoma&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead\u2019s Kite has successfully secured success in launching the first-ever <a href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">chimeric antigen receptor (CAR) T-cell therapy<\/a> in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy under accelerated approval.\u00a0<\/p>\n\n\n\n<p>Also known as axicabtagene ciloleucel, Yescarta\u2019s approval is based on the results from the study <strong>ZUMA-5<\/strong>. In this single-arm, open-label trial, 91% of patients with r\/r FL responded to the treatment, including an estimated 74% of them in continued remission at 18 months. However, the therapy will come with a boxed warning for cytokine release syndrome and neurologic toxicities.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">Follicular Lymphoma<\/a> is a type of indolent non-Hodgkin lymphoma (iNHL) in which malignant tumors grow gradually and turn aggressive with time. It is the most common form of indolent lymphoma and the second most common type of lymphoma around the world.\u00a0<\/p>\n\n\n\n<p>Yescart has already been ok\u2019d for relapsed or refractory large B-cell lymphoma, as well as for relapsed or refractory mantle cell lymphoma in combination with Tecartus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_data_from_COVID-19_trial_reports_Ridgeback_and_Merck\"><\/span><strong>Promising data from COVID-19 trial, reports Ridgeback and Merck&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck and Ridgeback Biotherapeutics released preliminary data from a Phase IIa trial investigating oral antiviral agent <strong>molnupiravir EIDD-2801\/MK-4482 <\/strong>for Covid-19.&nbsp;<\/p>\n\n\n\n<p>An oral ribonucleoside analog, Molnupiravir, inhibits the replication of multiple RNA viruses, including SARS-CoV-2. The therapy has demonstrated activity in several models of <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19<\/a>, including for prophylaxis, treatment, and prevention of transmission. It has also shown activity in SARS-CoV-1 and MERS.\u00a0<\/p>\n\n\n\n<p>The candidate was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University. Ridgeback. It was then licensed to Ridgeback Biotherapeutics, which obtained funding from Wayne and Wendy Holman, and Merck for its development.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AnaptysBios_shares_plummeted_after_its_lead_drug_fails_in_rare_skin_inflammation_phase_II_trial\"><\/span><strong>AnaptysBio\u2019s shares plummeted after its lead drug fails in rare skin inflammation phase II trial&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AnaptysBio shares fell owing to discouraging news of its antibody-drug, imsidolimab, failure in a rare inflammatory skin condition. The company announced that the drug did not prove to be upbeat. In Phase II clinical trial, imsidolimab failed to meet primary endpoints moderate-to-severe <a href=\"https:\/\/www.delveinsight.com\/report-store\/palmoplantar-pustulosis-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">palmoplantar pustulosis<\/a> (PPP). The <strong>POPLAR <\/strong>trial, however, showed that the drug is well-tolerated with no serious or severe side effects.\u00a0<\/p>\n\n\n\n<p>Palmoplantar pustulosis is a rare, recurring inflammatory disorder that is characterized by crops of sterile pustules on one or both hands and feet. The skin, later on, gets thick, scaly, and red with painful cracks. It is often seen in combination with plaque psoriasis.&nbsp;<\/p>\n\n\n\n<p>However, the boat has not sunk for imsidolimab. The company is evaluating imsidolimab in other five other immuno-dermatological indications such as acne, EGFRi-mediated skin toxicities, ichthyosis, <a href=\"https:\/\/www.delveinsight.com\/report-store\/hidradenitis-suppurativa-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">hidradenitis suppurativa<\/a>.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"After_AZ_Roche_discards_Tecentriq_for_Bladder_cancer_treatment\"><\/span><strong>After AZ, Roche discards Tecentriq for Bladder cancer treatment&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A few days back, AstraZeneca pulled out its candidate Imfinzi for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">bladder cancer,<\/a> a swiss pharma, Roche, also dropped its plans to proceed with its checkpoint inhibitor Tecentriq (atezolizumab) for the same.\u00a0<\/p>\n\n\n\n<p>Roche was evaluating Tecentriq in prior-platinum treated metastatic urothelial carcinoma (mUC). It had received accelerated approval by the USFDA for the same indication in 2016, which was based on the results from a cohort in the <strong>IMvigor210<\/strong> study. However, after its therapy failed to meet endpoints in confirmatory trials, the company decided to ditch it voluntarily.<\/p>\n\n\n\n<p>However, this decision of the company does not affect any other approved status of the therapy for other indication that includes <a href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">non-small cell lung cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/blog\/small-cell-lung-cancer-market\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">small cell lung cancer<\/a>, certain types of bladder cancer, a kind of triple-negative breast cancer, and liver cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead&#8217;s Kite Receives Expanded Approval for its CAR-T Yescarta&#8217;s in Follicular Lymphoma&nbsp; Gilead\u2019s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11872,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1873,794,395,18775,18776],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-11871","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anaptysbio","tag-gilead","tag-merck","tag-ridgeback","tag-roche-discards-tecentriq-for-bladder-cancer","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead\/Kite&#039;s Yescarta; Roche discards Tecentriq for bladder cancer<\/title>\n<meta name=\"description\" content=\"Gilead\/Kite&#039;s Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio&#039;s antibody-drug failure; Roche discards Tecentriq for bladder cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead\/Kite&#039;s Yescarta; Roche discards Tecentriq for bladder cancer\" \/>\n<meta property=\"og:description\" content=\"Gilead\/Kite&#039;s Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio&#039;s antibody-drug failure; Roche discards Tecentriq for bladder cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T11:38:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead\/Kite's Yescarta; Roche discards Tecentriq for bladder cancer","description":"Gilead\/Kite's Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","og_locale":"en_US","og_type":"article","og_title":"Gilead\/Kite's Yescarta; Roche discards Tecentriq for bladder cancer","og_description":"Gilead\/Kite's Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-03-09T11:38:28+00:00","article_modified_time":"2021-07-24T07:28:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche","name":"Gilead\/Kite's Yescarta; Roche discards Tecentriq for bladder cancer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use.jpg","datePublished":"2021-03-09T11:38:28+00:00","dateModified":"2021-07-24T07:28:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Gilead\/Kite's Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-ridgeback-anaptysbio-gilead-roche#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use.jpg","width":772,"height":482,"caption":"Gilead\/Kite's Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/09165732\/Roche-discards-Tecentriq-for-bladder-cancer-use-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AnaptysBio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ridgeback<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche discards Tecentriq for bladder cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AnaptysBio<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Ridgeback<\/span>","<span class=\"advgb-post-tax-term\">Roche discards Tecentriq for bladder cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 9, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 9, 2021 5:08 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Gilead\/Kite's Yescarta; Ridgeback\/ Merck in the COVID-19; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer  ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11871"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11871\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11872"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11871"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11871"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}